ClinicalTrials.gg
RecruitingNCT07385443DM1-HubUpdated Nov 3, 2026

The Spanish National Registry for Myotonic Dystrophy Type 1

An observational study in Myotonic Dystrophy 1, DM1 and Myotonic Dystrophy Type 1, sponsored by Fundació Institut Germans Trias i Pujol. Recruiting at 8 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Fundació Institut Germans Trias i Pujol · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 3, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 12 studies in Myotonic Dystrophy with a site in Spain — 9 open to participants now, 10 under way, 5 of them phase 3. Myotonic Dystrophy · Spain.

Started
2025
with 4 others
Observational
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
Fundació Institut Germans Trias i Pujol

Among the 12 studies in Myotonic Dystrophy with a site in Spain, this one is one of 5 that started in 2025, is the only observational one, and was the 10th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

9 of the 12 studies in Myotonic Dystrophy with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myotonic Dystrophy with a site in Spain, or all of them as a file.
02

Study summary

Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.

The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.

Read the detailed description

The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.

After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.

The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.

03

Conditions studied

  • Myotonic Dystrophy 1
  • DM1
  • Myotonic Dystrophy Type 1
  • Myotonic Dystrophy, Congenital
  • Steinert Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with Myotonic Dystrophy Type 1 (DM1) will volunteer to participate in this study. The study will be advertised through physician recommendations, outreach and educational activities directed at neuromuscular professionals, the registry website, national and local patient associations, and through patient-focused events, conferences, and scientific meetings across Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for the registry
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Myotonic Dystrophy Type 1 (DM1)

    The group included Individuals with a confirmed genetic diagnosis of Myotonic Dystrophy Type 1 (DM1)

    Other: Patient Registry

  • Control

    The group included control subjects as individuals without a genetic diagnosis of Myotonic Dystrophy Type 1 (DM1).

    Other: Patient Registry

Interventions

  • OtherPatient Registry

    Patient Registry

06

What researchers measure

Primary outcomes

  1. Genomic Caracterization

    Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling.

    Time frame: 1 year, year 1

Secondary outcomes

  1. Proteomic Characterization

    Biomarker evaluation

    Time frame: 1 year, year 1

  2. WAIS IV neuropsychological tests

    IQ, memory, attention, language

    Time frame: 2 years, year 1

  3. vHOT

    Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed

    Time frame: 1 year, year 1

  4. Muscular Impairment Rating Scale (MIRS)

    The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy. Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment.

    Time frame: 1 year, year 1

  5. Hand Grip Strength

    Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg). For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis. Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment.

    Time frame: 1 year, year 1

  6. 6MWT

    Six-Minute Walk Test

    Time frame: 1 year, year 1

  7. 10MWRT

    10-meter Walk/Run Test

    Time frame: 1 year, year 1

  8. 30CST

    30-Second Chair Stand Test

    Time frame: 1 year, year 1

  9. FVC

    Forced Vital Capacity (L)

    Time frame: 1 year, year 1

  10. Electrocardiogram (ECG)

    The following ECG-derived parameters and abnormalities are recorded: * PR interval duration (milliseconds) * QRS complex duration (milliseconds) * Presence of atrioventricular block (AV block) (yes/no), and AV block grade when present (first degree, second degree Mobitz I, second degree Mobitz II, third degree) * Presence of supraventricular arrhythmias (yes/no) * Presence of ventricular arrhythmias (yes/no) * Other electrocardiographic abnormalities, recorded as free text when applicable All measurements are extracted from the ECG tracing according to standard clinical practice. Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function.

    Time frame: 1 year, year 1

  11. BMI

    Body Mass Index

    Time frame: 1 year, year 1

  12. OBGYN events

    Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information.

    Time frame: 1 year, year 1

  13. GI symptomatology

    Collection of participant-reported gastrointestinal symptoms and related clinical information.

    Time frame: 1 year, year 1

  14. MBS (Myotonia Behaviour Scale)

    Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities. The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia: 0: No muscle stiffness 1. Mild stiffness present but easily ignored 2. Stiffness present and occasionally noticeable but does not interfere with daily activities 3. Stiffness requiring increased concentration to perform certain tasks or activities 4. Stiffness interfering with all tasks and daily activities 5. Severe, disabling stiffness requiring constant movement to avoid complete motor blockage Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia.

    Time frame: 1 year, year 1

  15. Modified Rankin Scale (mRS)

    Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities. The scale ranges from 0 to 6, with higher scores indicating greater disability or death: 0: No symptoms 1. No significant disability; able to carry out all usual activities despite symptoms 2. Slight disability; unable to perform all previous activities but able to manage own affairs without assistance 3. Moderate disability; requiring some help but able to walk without assistance 4. Moderately severe disability; unable to walk without assistance and unable to attend to bodily needs without help 5. Severe disability; bedridden, incontinent, and requiring constant nursing care and attention 6. Death

    Time frame: 1 year, year 1

  16. Patient-Reported Outcome: Quality of life

    INQoL (Individualized Neuromuscular Quality of Life Questionnaire)

    Time frame: 1 year, year 1

  17. Patient-Reported Outcome: Fatigue

    FSS (Fatigue Severity Scale )

    Time frame: 1 year, year 1

  18. Patient-Reported Outcome: Dietary Habits

    MEDAS-14 (Mediterranean Diet Adherence Screener)

    Time frame: 1 year, year 1

  19. Patient-Reported Outcome: Sleepiness

    DSS (Daytime Sleepiness Scale)

    Time frame: 1 year, year 1

  20. Patient-Reported Outcome: Apathy

    AES (Apathy Evaluation Scale)

    Time frame: 1 year, year 1

  21. Patient-Reported Outcome: Physical Activity

    IPAQ (International Physical Activity Questionnaire)

    Time frame: 1 year, year 1

  22. Patient-Reported Outcome: Mental Health

    MHI-5 (Mental Health Inventory)

    Time frame: 1 year, year 1

07

Study locations

8 of 8 sites recruiting
  • Hospitals within the DM1 network
    Multiple Locations, Andalusia, Spain
    Recruiting
    • Dr. Macarena Cabrera · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Macarena Cabrera · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Basque Country, Spain
    Recruiting
    • Dr. Andone Sistiaga · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Andone Sistiaga · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Canary Islands, Spain
    Recruiting
    • Dr. Jorge Alonso · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Jorge Alonso · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Cantabria, Spain
    Recruiting
    • Dr. Ana Lara Pelayo · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Ana Lara Pelayo · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Castilla-La Macha, Spain
    Recruiting
    • Dr. Jorge García · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Jorge García · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Catalonia, Spain
    Recruiting
    • Dr. Sebastián Figueroa · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Sebastián Figueroa · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Madrid, Spain
    Recruiting
    • Dr. Gerardo Gutiérrez · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Gerardo Gutiérrez · Principal investigator
  • Hospitals within the DM1 network
    Multiple Locations, Valencia, Spain
    Recruiting
    • Dr. Nuria Muelas · Contactdm1-hub@igtp.cat · (+34) 93 554 3050
    • Dr. Nuria Muelas · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 18 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2035, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Feb 4, 2026
StartActual
Jun 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2035was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 31, 2026→Dec 31, 2035
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Study completion Dec 31, 2026→Dec 31, 2035

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07385443
Lead sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
Instituto de Investigacion Sanitaria INCLIVA, Biobizkaia Health Research Institute, Biogipuzkoa Health Research Institute, Germans Trias i Pujol Hospital, Hospital Infanta Sofia, Hospital de Basurto, Hospital Donostia, Hospitales Universitarios Virgen del Rocío, Hospital Universitario Marqués de Valdecilla, Complejo Hospitalario Universitario de Albacete, Hospital Universitario La Fe, Hospital Univeritario Ntra. Sra. de la Candelaria
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Jun 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Nov 3, 2026

Study contacts

Gisela Nogales Gadea, Ph.D.
Contact
gnogales@igtp.cat
(+34) 93 554 3050
Alvaro S Larran Mottino, Ph.D.
Contact
alarran@igtp.cat
Gisela Nogales Gadea, Ph.D.
study director · Germans Trias i Pujol Research Institute
Arturo Lopez Castel, Ph.D.
principal investigator · INCLIVA Instituto de Investigación Sanitaria
Virginia Arechavala-Gomeza, Ph.D.
principal investigator · IIS Biobizkaia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion